References
- Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827–38
- Ballantyne D, Ballantyne F C. Review article: Thiazides, beta blockers and lipoproteins. Postgrad Med J 1983; 59: 483–8
- Wolinsky H. Review: The effects of beta-adrenergic blocking agents on blood lipid levels. Clin Cardiol 1987; 10: 561–6
- Northcote R J. Beta blockers, lipids and coronary arteriosclerosis: fact or fiction?. Br Med J 1988; 296: 731
- Miller N E. Effects of adrenoreceptor-blocking drugs on plasma lipoprotein concentrations. Am J Cardiol 1987; 60: 17E–23E
- Avogardo P, Bittolo Bon G, Gazzolato G, Quinci G B. Are apolipoproteins better discriminators than lipids for atherosclerosis. Lancet 1987; i: 901–4
- Sedlis S P, Ludbrook P A, Sobel B E, Schonfeld G. Plasma apoproteins and the severity of coronary artery disease. Circulation 1986; 73: 978–86
- Wasenius A, Stugaard M, Otterstad J E, Froeyshov D. Diurnal and serial variability of lipoproteins. Scand J Lab Clin Invest 1990; 50: 635–42
- Schettler G, Nussel E. Massnahmen zur prevention der arteriosklerosie. Arbeitsmed Sozialmed Praeventivmed 1975; 10: 25–9
- Friedewald W T, Levy R I, Fredrickson D S. Estimation of the concentration of LDL-cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502
- Betteridge D J. High density lipoprotein and coronary heart disease. How it protects is still a mystery. Br Med J 1989; 298: 974–5
- Boettiger L-E, Carlson L A. Risk factors for ichaemic vascular death for men in the Stockholm prospective study. Atherosclerosis 1980; 36: 389–408
- Åberg H, Lithell H, Selinus I, Hedstrand H. Serum triglycerides are a risk factor for myocardial infarction but not for angina pectoris. Results from a 10-year follow-up of Uppsala primary preventive study. Atherosclerosis 1985; 54: 89–97
- Castelli W P. The triglyceride issue: A view from Framingham. Am Heart J 1986; 112: 432–7
- Austin M A. Epidemiologic associations between hypertriglyceridemia and coronary heart disease. Sem Thrombosis Hemostasis 1988; 44: 137–48
- Pocock S J, Shaper A G, Philips A N. Concentrations of high density lipoprotein cholesterol, triglycerides, and total cholesterol in ischaemic heart disease. Br Med J 1989; 298: 998–1002
- Kaplan N M. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989; 149: 1514–20
- Berglund G, Andersson O. Beta-blockers or diuretics in hypertension? A six year follow-up of blood pressure and metabolic side effects. Lancet 1981; i: 741–7
- Helgeland A, Hjermann I, Leren P. High density lipoprotein cholesterol and anti-hypertensive drugs: the Oslo study. Br Med J 1978; 278: 403
- Helgeland A, Hjermann I, Holme I, Leren P. Serum triglycerides and serum uric acid in untreated and thiazide treated patients with mild hypertension. Am J Med 1978; 64: 34–8
- Gluck Z, Weidmann P, Mordasini R, et al. Increased serum low-density lipoprotein cholesterol in men treated short term with the diuretic chlortalidone. Metabolism 1980; 29: 240–5
- Goldman A I, Steele B W, Schnaper H W, Fitz A E, Frohlich E D, Perry H M. Serum lipoprotein levels during chlortalidone therapy. J Am Med Assoc 1980; 244: 1691–5
- Gordon T, Castelli W P, Hjortland M C, Kannel W B, Dawber T R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62: 707–13
- Castelli W P, Garrison R J, Wilson P F, Abbot R D, Kalousdian S, Kannel W B. Incidence of coronary heart disease and lipoprotein levels. The Framingham study. J Am Med Assoc 1986; 256: 2835–8
- Castelli W. Epidemiology of coronary heart disease. Am J Med 1984; 76(Suppl. 2A)4–12
- Cruickshank J M. Why has the primary prevention of myocardial infarction in the treatment of hypertension been so elusive?. J Human Hypertens 1987; 1: 73–81
- Kaplan J R, Mannuck S B, Adams M R, Clarkson T B. The effects of beta-adrenergic blocking agents on atherosclerosis and its complications. Eur Heart J 1987; 8: 928–44
- Cruickshank J M, Smith J C. The beta-receptor, atheroma and cardiovascular damage. Pharm Ther 1989; 42: 385–404